carnitine has been researched along with Benign Neoplasms in 66 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-carnitine, a popular complementary and alternative medicine product, is used by patients with cancer for the treatment of fatigue, the most commonly reported symptom in this patient population." | 9.16 | L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. ( Ansari, B; Cella, D; Cruciani, RA; Fisch, MJ; Manola, J; Zhang, JJ, 2012) |
| " antioxidants) with carnitine + celecoxib ± megestrol acetate for the treatment of cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints were increase of lean body mass (LBM) and improvement of total daily physical activity." | 9.16 | Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. ( Antoni, G; Astara, G; Cau, MC; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Mela, Q; Montaldo, L; Mura, M; Panzone, F; Serpe, R; Tanca, FM, 2012) |
| "Carnitine deficiency is among the many metabolic disturbances that may contribute to fatigue in patients with cancer." | 9.12 | Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. ( Cruciani, RA; Culliney, B; Dvorkin, E; Esteban-Cruciani, N; Homel, P; Lapin, J; Malamud, S; Portenoy, RK, 2006) |
| "Carnitine deficiency has been implicated as a potential pathway for cancer-related fatigue that could be treated with carnitine supplementation." | 8.95 | Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis. ( Isenring, E; Itsiopoulos, C; Kelly, J; Marshall, S; Marx, W; Opie, RS; Teleni, L, 2017) |
| "This study suggests that there is an association between urinary carnitine levels and self-reported fatigue." | 7.85 | Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy. ( Ikezaki, T; Inomata, M; Kajiura, S; Kambara, K; Kashii, T; Miwa, T; Okazawa, S; Suzuki, K; Tanabe, K, 2017) |
| "Carnitine deficiency has been found in cancer patients and has been associated with fatigue." | 7.83 | A cross-sectional study of carnitine deficiency and fatigue in pediatric cancer patients. ( Goldman, S; Haertling, T; Lai, JS; Rademaker, AW; Weinstein, J, 2016) |
| " Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8." | 7.81 | Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015) |
| "Patients undergoing chemotherapy are at risk of carnitine deficiency, and carnitine supplementation has been demonstrated to improve cancer-related fatigue." | 7.80 | [Experience with levocarnitine chloride supplementation for the treatment of fatigue in cancer patients undergoing chemotherapy]. ( Matsunaga, N; Nakagawa, Y; Yanagawa, K, 2014) |
| "Cancer cachexia (CC), a progressive loss of body mass, leads to malnutrition and deficiencies of essential substances including polyunsaturated fatty acids (PUFAs) and L-carnitine (LC)." | 7.78 | L-carnitine and cancer cachexia. II. Effects of lipid emulsion used in total parenteral nutrition on parameters of hemostasis and inflammatory state in L-carnitine deficiency in myocytes. ( Ciesielski, M; Jankun, J; Kawecki, K; Kruszewski, WJ; Lysiak-Szydłowska, W; Szajewski, M; Szefel, J, 2012) |
| "Although cancer patients had carnitine deficiency and lower carnitine stores, these did not affect resting energy expenditure, total food intake, or plasma lysine and methionine levels." | 6.78 | Lower carnitine plasma values from malnutrition cancer patients. ( Demenice, R; dos Santos, JS; Jordão, AA; Leme, IA; Marchini, JS; Portari, GV; Rabito, EI, 2013) |
| "A decrease in skeletal muscle LC in cancer patients with CC (BMI ≤ 19 kg/m(2)) correlates with an increase in its plasma levels and increased renal excretion." | 6.77 | L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia. ( Aleksandrowicz-Wrona, E; Ciesielski, M; Jankun, J; Kawecki, K; Kruszewski, WJ; Lysiak-Szydłowska, W; Szajewski, M; Szefel, J, 2012) |
| "Fatigue was assessed by the Functional Assessment of Cancer Therapy-Fatigue quality of life questionnaire." | 6.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "These effects of L-carnitine on cancer cachexia mice were accompanied by the upregulation of mRNA level of CPT I and II and increased enzyme activity of CPT I in the liver, as well as the downregulation of serum TNF-α and IL-6 levels." | 5.37 | L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase. ( Chen, Q; Liu, B; Liu, S; Wu, HJ; Wu, JP; Zhang, ZQ; Zhu, L, 2011) |
| "One mechanism contributing to cancer-related fatigue involves abnormalities in adenosine triphosphate synthesis caused by carnitine deficiency." | 5.35 | Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009) |
| "Fatigue is a multidimensional symptom that is described in terms of perceived energy, mental capacity, and psychological status: it can impair daily functioning and lead to negative effects on quality of life." | 5.33 | Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. ( Astara, G; Deiana, L; Dessì, M; Gramignano, G; Lamonica, G; Lusso, MR; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Serpe, R; Spiga, C, 2006) |
| "L-carnitine, a popular complementary and alternative medicine product, is used by patients with cancer for the treatment of fatigue, the most commonly reported symptom in this patient population." | 5.16 | L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. ( Ansari, B; Cella, D; Cruciani, RA; Fisch, MJ; Manola, J; Zhang, JJ, 2012) |
| " antioxidants) with carnitine + celecoxib ± megestrol acetate for the treatment of cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints were increase of lean body mass (LBM) and improvement of total daily physical activity." | 5.16 | Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. ( Antoni, G; Astara, G; Cau, MC; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Mela, Q; Montaldo, L; Mura, M; Panzone, F; Serpe, R; Tanca, FM, 2012) |
| "Three hundred thirty-two assessable patients with cancer-related anorexia/cachexia syndrome were randomly assigned to one of five treatment arms: arm 1, medroxyprogesterone (500 mg/day) or megestrol acetate (320 mg/day); arm 2, oral supplementation with eicosapentaenoic acid; arm 3, L-carnitine (4 g/day); arm 4, thalidomide (200 mg/day); and arm 5, a combination of the above." | 5.14 | Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. ( Contu, P; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Panzone, F; Serpe, R, 2010) |
| "Three hundred and thirty-two assessable patients with cancer-related anorexia/cachexia syndrome (CACS) were randomly assigned to one of five arms of treatment: 1--medroxyprogesterone 500 mg/d or megestrol acetate 320 mg/d; 2--oral supplementation with eicosapentaenoic acid (EPA); 3--L-carnitine 4 g/d; 4--thalidomide 200 mg/d; 5--a combination of the above." | 5.14 | Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. ( Mantovani, G, 2010) |
| "Carnitine deficiency is among the many metabolic disturbances that may contribute to fatigue in patients with cancer." | 5.12 | Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. ( Cruciani, RA; Culliney, B; Dvorkin, E; Esteban-Cruciani, N; Homel, P; Lapin, J; Malamud, S; Portenoy, RK, 2006) |
| " Because of its trophic action on the myocardial tissue, the use of L-carnitine has been evaluated during IL-2 therapy in advanced cancer patients with clinically important cardiac diseases." | 5.07 | Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy. ( Barni, S; Galli, MA; Lissoni, P; Tancini, G, 1993) |
| "Carnitine deficiency has been implicated as a potential pathway for cancer-related fatigue that could be treated with carnitine supplementation." | 4.95 | Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis. ( Isenring, E; Itsiopoulos, C; Kelly, J; Marshall, S; Marx, W; Opie, RS; Teleni, L, 2017) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| "CAM interventions tested for cancer-related fatigue include acupuncture, aromatherapy, adenosine triphosphate infusions, energy conservation and activity management, healing touch, hypnosis, lectin-standardized mistletoe extract, levocarnitine, massage, mindfulness-based stress reduction, polarity therapy, relaxation, sleep promotion, support group, and Tibetan yoga." | 4.84 | A critical review of complementary therapies for cancer-related fatigue. ( Barton, DL; Bauer, BA; Loprinzi, CL; Sood, A, 2007) |
| "In the continuous effort to develop more efficacious strategies against the anorexia/cachexia syndrome, carnitine and nicotine may represent a further therapeutic tool." | 4.83 | Antimyopathic effects of carnitine and nicotine. ( Cascino, A; Guijarro, A; Laviano, A; Meguid, MM; Molfino, A; Muscaritoli, M; Preziosa, I; Rossi Fanelli, F, 2006) |
| "This study suggests that there is an association between urinary carnitine levels and self-reported fatigue." | 3.85 | Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy. ( Ikezaki, T; Inomata, M; Kajiura, S; Kambara, K; Kashii, T; Miwa, T; Okazawa, S; Suzuki, K; Tanabe, K, 2017) |
| "Associations between pre-diagnostic levels of 120 circulating metabolites (acylcarnitines, amino acids, biogenic amines, phosphatidylcholines, sphingolipids, and hexoses) and the risks of breast, prostate, and colorectal cancer were evaluated by Cox regression analyses using data of a prospective case-cohort study including 835 incident cancer cases." | 3.83 | Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study. ( Boeing, H; Floegel, A; Johnson, T; Kaaks, R; Kühn, T; Otto, W; Rolle-Kampczyk, U; Sookthai, D; von Bergen, M, 2016) |
| "Carnitine deficiency has been found in cancer patients and has been associated with fatigue." | 3.83 | A cross-sectional study of carnitine deficiency and fatigue in pediatric cancer patients. ( Goldman, S; Haertling, T; Lai, JS; Rademaker, AW; Weinstein, J, 2016) |
| " Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8." | 3.81 | Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015) |
| "Patients undergoing chemotherapy are at risk of carnitine deficiency, and carnitine supplementation has been demonstrated to improve cancer-related fatigue." | 3.80 | [Experience with levocarnitine chloride supplementation for the treatment of fatigue in cancer patients undergoing chemotherapy]. ( Matsunaga, N; Nakagawa, Y; Yanagawa, K, 2014) |
| "Cancer cachexia (CC), a progressive loss of body mass, leads to malnutrition and deficiencies of essential substances including polyunsaturated fatty acids (PUFAs) and L-carnitine (LC)." | 3.78 | L-carnitine and cancer cachexia. II. Effects of lipid emulsion used in total parenteral nutrition on parameters of hemostasis and inflammatory state in L-carnitine deficiency in myocytes. ( Ciesielski, M; Jankun, J; Kawecki, K; Kruszewski, WJ; Lysiak-Szydłowska, W; Szajewski, M; Szefel, J, 2012) |
| "It can be concluded that L-carnitine supplementation may be a good approach for a multi-targeted therapy for the treatment of cancer-related cachexia." | 3.78 | L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. ( Argilés, JM; Betancourt, A; Busquets, S; Capdevila, E; López-Soriano, FJ; Macciò, A; Madeddu, C; Mantovani, G; Marmonti, E; Orpí, M; Pin, F; Serpe, R; Toledo, M, 2012) |
| "Carnitine is an essential cofactor in the lipid metabolic pathways." | 3.01 | Clinical Significance of Carnitine in the Treatment of Cancer: From Traffic to the Regulation. ( Farahzadi, R; Hejazi, MS; Jafari, S; Molavi, O; Montazersaheb, S; Pishgahzadeh, E, 2023) |
| " Because of the cardiotoxic adverse effects, use is limited." | 2.82 | Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review. ( Moustafa, I; Oosthuizen, F; Saka, S; Viljoen, M, 2022) |
| "Although cancer patients had carnitine deficiency and lower carnitine stores, these did not affect resting energy expenditure, total food intake, or plasma lysine and methionine levels." | 2.78 | Lower carnitine plasma values from malnutrition cancer patients. ( Demenice, R; dos Santos, JS; Jordão, AA; Leme, IA; Marchini, JS; Portari, GV; Rabito, EI, 2013) |
| "A decrease in skeletal muscle LC in cancer patients with CC (BMI ≤ 19 kg/m(2)) correlates with an increase in its plasma levels and increased renal excretion." | 2.77 | L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia. ( Aleksandrowicz-Wrona, E; Ciesielski, M; Jankun, J; Kawecki, K; Kruszewski, WJ; Lysiak-Szydłowska, W; Szajewski, M; Szefel, J, 2012) |
| "To evaluate the effect of the anti-cancer drug carboplatin on plasma concentrations and urinary excretion of L-carnitine (LC) and its main ester, acetyl-L-carnitine (ALC), in cancer patients." | 2.73 | Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ( Bisonni, R; Calvani, M; D'Iddio, S; Graziano, F; Lippe, P; Mancinelli, A, 2007) |
| "To establish the safety, pharmacokinetic parameters, maximum-tolerated dose, and recommended dose of aplidine, a novel marine cyclodepsipeptide, in patients with advanced cancer." | 2.71 | Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. ( Ady-Vago, N; Armand, JP; Chièze, S; Delbaldo, C; Faivre, S; Guzman, C; Jimeno, J; Lopez-Lazaro, L; Lozahic, S; Martin, JA; Pico, F; Raymond, E, 2005) |
| "Fatigue was assessed by the Functional Assessment of Cancer Therapy-Fatigue quality of life questionnaire." | 2.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "The carnitine-treated group in the randomized clinical study showed also a significant decrease in the plasma glutamate levels but only a moderate and statistically not significant increase in the relative glutamate uptake in the lower extremities." | 2.69 | Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases. ( Babylon, A; Böhles, H; Breitkreutz, R; Dröge, W; Edler, L; Hack, V; Hagmüller, E; Holm, E; Schuster, K; Tokus, M, 2000) |
| "CPTI activates FAO and fuels cancer growth via ATP and NADPH production, constituting an essential part of cancer metabolism adaptation." | 2.53 | Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. ( Deng, F; Liu, X; Qu, Q; Wang, QJ; Zeng, F, 2016) |
| "Cancer cachexia is a severe inflammatory metabolic syndrome accounting for fatigue, an impairment of normal activities and, eventually, death." | 2.52 | Advances in pharmacologic strategies for cancer cachexia. ( Gramignano, G; Macciò, A; Madeddu, C; Mantovani, G, 2015) |
| "Many patients receiving cancer treatment use micronutrient supplements, with the intention to complement their cancer treatment, or help them cope with the therapy- and disease-associated side-effects." | 2.49 | [Micronutrients in oncology. Current data about vitamin D, selenium, L-carnitine and vitamin C]. ( Gröber, U; Holzhauer, P; Kisters, K; Mücke, R, 2013) |
| " Fatigue is the most common side effect of radiotherapy, while others include nausea, hair loss, skin irritation, anemia, infertility, cardiovascular disease, cognitive impairment and even the development of second cancers." | 2.47 | A review of the logistic role of L-carnitine in the management of radiation toxicity and radiotherapy side effects. ( Alhomida, AS; Khan, HA, 2011) |
| "Some important anticancer drugs contribute to dysfunction of the carnitine system in nontumor tissues, which is reversed by carnitine treatment, without affecting anticancer therapeutic efficacy." | 2.41 | Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. ( Barbarisi, A; Benatti, P; Calvani, M; Nicolai, R; Peluso, G; Reda, E, 2000) |
| "Acylcarnitines have been identified in human and animal metabolomic-profiling studies as urinary markers of radiation exposure, a result which is consistent with their cytoprotective effects and roles in energy metabolism." | 1.56 | Quantitation of Urinary Acylcarnitines by DMS-MS/MS Uncovers the Effects of Total Body Irradiation in Cancer Patients. ( Barker, CA; Clasquin, M; Coy, SL; Fornace, AJ; Laiakis, EC; Pfefferkorn, JA; Vera, NB; Vouros, P, 2020) |
| "The mechanisms underlying cancer cachexia - the proximate cause of at least 20% of cancer-related deaths - have until recently remained rather obscure." | 1.51 | Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia. ( Iloki-Assanga, S; Lujany, LML; McCarty, MF, 2019) |
| "Median survival in terminally ill cancer patients after enrollment was 38." | 1.46 | Plasma L-carnitine levels in terminally ill cancer patients receiving only palliative care. ( Fukushima, T; Gomi, D; Kobayashi, T; Koizumi, T; Mamiya, K; Matsushita, H; Sakamoto, A; Sekiguchi, N; Tsukahara, Y, 2017) |
| "Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared with the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose." | 1.40 | Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines. ( Armenian, SH; Bhatia, S; Freyer, DR; Gelehrter, SK; Herrera, C; Landier, W; Mascarenhas, L; Menteer, JD; Reichman, L; Vase, T; Venkataraman, K; Venkatramani, R; Wilson, KD, 2014) |
| "However, the resistance of many primary tumors and cancer cells to TRAIL poses a challenge." | 1.38 | Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax. ( Cho, DH; Hwang, JJ; Jeong, SY; Jin, DH; Kim, I; Kim, JC; Kim, JH; Kim, JO; Lee, SJ; Park, SH; Park, SJ, 2012) |
| "Based on Warburg's theory that most cancer cells mainly depend on glycolysis for ATP generation, we hypothesize that, LC treatment would lead to disturbance of cellular metabolism and cytotoxicity in cancer cells." | 1.38 | L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. ( Dou, QP; Guan, L; Guo, H; Huang, H; Li, B; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Song, W; Wang, X; Xu, L; Yang, C; Zhang, C, 2012) |
| "These effects of L-carnitine on cancer cachexia mice were accompanied by the upregulation of mRNA level of CPT I and II and increased enzyme activity of CPT I in the liver, as well as the downregulation of serum TNF-α and IL-6 levels." | 1.37 | L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase. ( Chen, Q; Liu, B; Liu, S; Wu, HJ; Wu, JP; Zhang, ZQ; Zhu, L, 2011) |
| "One mechanism contributing to cancer-related fatigue involves abnormalities in adenosine triphosphate synthesis caused by carnitine deficiency." | 1.35 | Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009) |
| "Fatigue is a multidimensional symptom that is described in terms of perceived energy, mental capacity, and psychological status: it can impair daily functioning and lead to negative effects on quality of life." | 1.33 | Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. ( Astara, G; Deiana, L; Dessì, M; Gramignano, G; Lamonica, G; Lusso, MR; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Serpe, R; Spiga, C, 2006) |
| "In addition, in each form of cancer the pattern of aldehydes appeared to be unique when compared to controls, or to others forms of cancer." | 1.30 | Cytotoxic aldehydes as possible markers for childhood cancer. ( Fisher, LJ; Greenberg, M; Lau, R; Lehotay, DC; Luo, X; Yazdanpanah, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.06) | 18.7374 |
| 1990's | 5 (7.58) | 18.2507 |
| 2000's | 17 (25.76) | 29.6817 |
| 2010's | 34 (51.52) | 24.3611 |
| 2020's | 6 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Moustafa, I | 1 |
| Saka, S | 1 |
| Viljoen, M | 1 |
| Oosthuizen, F | 1 |
| Wedekind, R | 1 |
| Rothwell, JA | 1 |
| Viallon, V | 1 |
| Keski-Rahkonen, P | 1 |
| Schmidt, JA | 1 |
| Chajes, V | 1 |
| Katzke, V | 1 |
| Johnson, T | 2 |
| Santucci de Magistris, M | 1 |
| Krogh, V | 1 |
| Amiano, P | 1 |
| Sacerdote, C | 1 |
| Redondo-Sánchez, D | 1 |
| Huerta, JM | 1 |
| Tjønneland, A | 1 |
| Pokharel, P | 1 |
| Jakszyn, P | 1 |
| Tumino, R | 1 |
| Ardanaz, E | 1 |
| Sandanger, TM | 1 |
| Winkvist, A | 1 |
| Hultdin, J | 1 |
| Schulze, MB | 1 |
| Weiderpass, E | 1 |
| Gunter, MJ | 1 |
| Huybrechts, I | 1 |
| Scalbert, A | 1 |
| Liu, T | 2 |
| Liu, C | 3 |
| Wang, X | 3 |
| Wei, Y | 2 |
| Li, S | 2 |
| Song, Y | 2 |
| Chen, P | 2 |
| Liu, L | 2 |
| Wang, B | 2 |
| Shi, H | 2 |
| Farahzadi, R | 1 |
| Hejazi, MS | 1 |
| Molavi, O | 1 |
| Pishgahzadeh, E | 1 |
| Montazersaheb, S | 1 |
| Jafari, S | 1 |
| McCarty, MF | 1 |
| Iloki-Assanga, S | 1 |
| Lujany, LML | 1 |
| Simón-Manso, Y | 1 |
| Marupaka, R | 1 |
| Yan, X | 1 |
| Liang, Y | 1 |
| Telu, KH | 1 |
| Mirokhin, Y | 1 |
| Stein, SE | 1 |
| Hishida, A | 1 |
| Watanabe, R | 1 |
| Hattori, Y | 1 |
| Okugawa, Y | 1 |
| Shirai, Y | 1 |
| Miki, C | 1 |
| Juraszek, B | 1 |
| Nałęcz, KA | 1 |
| Vera, NB | 1 |
| Coy, SL | 1 |
| Laiakis, EC | 1 |
| Fornace, AJ | 1 |
| Clasquin, M | 1 |
| Barker, CA | 1 |
| Pfefferkorn, JA | 1 |
| Vouros, P | 1 |
| Li, Y | 1 |
| Sutrisno, L | 1 |
| Hou, Y | 1 |
| Fei, Y | 1 |
| Xue, C | 1 |
| Hu, Y | 1 |
| Li, M | 1 |
| Luo, Z | 1 |
| Gomi, D | 2 |
| Tanaka, A | 1 |
| Fukushima, T | 2 |
| Kobayashi, T | 2 |
| Matsushita, H | 2 |
| Sekiguchi, N | 2 |
| Sakamoto, A | 2 |
| Sasaki, S | 1 |
| Mamiya, K | 2 |
| Koizumi, T | 2 |
| Tsukahara, Y | 1 |
| Marx, W | 1 |
| Teleni, L | 1 |
| Opie, RS | 1 |
| Kelly, J | 1 |
| Marshall, S | 1 |
| Itsiopoulos, C | 1 |
| Isenring, E | 1 |
| Melone, MAB | 1 |
| Valentino, A | 1 |
| Margarucci, S | 1 |
| Galderisi, U | 1 |
| Giordano, A | 1 |
| Peluso, G | 3 |
| Ringseis, R | 1 |
| Keller, J | 1 |
| Eder, K | 1 |
| Rabito, EI | 1 |
| Leme, IA | 1 |
| Demenice, R | 1 |
| Portari, GV | 1 |
| Jordão, AA | 1 |
| dos Santos, JS | 1 |
| Marchini, JS | 1 |
| Gröber, U | 1 |
| Mücke, R | 1 |
| Holzhauer, P | 1 |
| Kisters, K | 1 |
| Pochini, L | 1 |
| Scalise, M | 1 |
| Galluccio, M | 1 |
| Indiveri, C | 1 |
| Armenian, SH | 2 |
| Gelehrter, SK | 1 |
| Vase, T | 1 |
| Venkatramani, R | 1 |
| Landier, W | 1 |
| Wilson, KD | 1 |
| Herrera, C | 1 |
| Reichman, L | 1 |
| Menteer, JD | 1 |
| Mascarenhas, L | 1 |
| Freyer, DR | 1 |
| Venkataraman, K | 1 |
| Bhatia, S | 1 |
| Hooke, MC | 2 |
| McCarthy, K | 2 |
| Taylor, O | 1 |
| Hockenberry, MJ | 2 |
| Yanagawa, K | 1 |
| Matsunaga, N | 1 |
| Nakagawa, Y | 1 |
| Galani, A | 1 |
| Tsitsias, V | 1 |
| Stellas, D | 1 |
| Psycharis, V | 1 |
| Raptopoulou, CP | 1 |
| Karaliota, A | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Stone, P | 1 |
| Radbruch, L | 1 |
| Madeddu, C | 6 |
| Mantovani, G | 7 |
| Gramignano, G | 3 |
| Macciò, A | 6 |
| Lai, JS | 1 |
| Haertling, T | 1 |
| Weinstein, J | 1 |
| Rademaker, AW | 1 |
| Goldman, S | 1 |
| Kühn, T | 1 |
| Floegel, A | 1 |
| Sookthai, D | 1 |
| Rolle-Kampczyk, U | 1 |
| Otto, W | 1 |
| von Bergen, M | 1 |
| Boeing, H | 1 |
| Kaaks, R | 1 |
| Qu, Q | 1 |
| Zeng, F | 1 |
| Liu, X | 1 |
| Wang, QJ | 1 |
| Deng, F | 1 |
| Ikezaki, T | 1 |
| Suzuki, K | 1 |
| Kambara, K | 1 |
| Inomata, M | 1 |
| Okazawa, S | 1 |
| Kajiura, S | 1 |
| Miwa, T | 1 |
| Tanabe, K | 1 |
| Kashii, T | 1 |
| Cruciani, RA | 4 |
| Dvorkin, E | 3 |
| Homel, P | 3 |
| Culliney, B | 3 |
| Malamud, S | 3 |
| Lapin, J | 3 |
| Portenoy, RK | 2 |
| Esteban-Cruciani, N | 3 |
| Gregurich, M | 1 |
| Serpe, R | 5 |
| Massa, E | 3 |
| Dessì, M | 4 |
| Panzone, F | 3 |
| Contu, P | 2 |
| Liu, S | 2 |
| Wu, HJ | 1 |
| Zhang, ZQ | 1 |
| Chen, Q | 1 |
| Liu, B | 1 |
| Wu, JP | 1 |
| Zhu, L | 1 |
| Khan, HA | 1 |
| Alhomida, AS | 1 |
| Antoni, G | 1 |
| Cau, MC | 1 |
| Montaldo, L | 1 |
| Mela, Q | 1 |
| Mura, M | 1 |
| Astara, G | 2 |
| Tanca, FM | 2 |
| Szefel, J | 2 |
| Kruszewski, WJ | 2 |
| Ciesielski, M | 2 |
| Szajewski, M | 2 |
| Kawecki, K | 2 |
| Aleksandrowicz-Wrona, E | 1 |
| Jankun, J | 2 |
| Lysiak-Szydłowska, W | 2 |
| Busquets, S | 1 |
| Toledo, M | 1 |
| Betancourt, A | 1 |
| Marmonti, E | 1 |
| Orpí, M | 1 |
| Pin, F | 1 |
| Capdevila, E | 1 |
| López-Soriano, FJ | 1 |
| Argilés, JM | 1 |
| Zhang, JJ | 1 |
| Manola, J | 1 |
| Cella, D | 1 |
| Ansari, B | 1 |
| Fisch, MJ | 1 |
| Park, SJ | 2 |
| Park, SH | 1 |
| Kim, JO | 1 |
| Kim, JH | 1 |
| Hwang, JJ | 1 |
| Jin, DH | 1 |
| Jeong, SY | 1 |
| Lee, SJ | 1 |
| Kim, JC | 1 |
| Kim, I | 1 |
| Cho, DH | 1 |
| Huang, H | 1 |
| Liu, N | 1 |
| Guo, H | 1 |
| Liao, S | 1 |
| Li, X | 1 |
| Yang, C | 1 |
| Song, W | 1 |
| Guan, L | 1 |
| Li, B | 1 |
| Xu, L | 1 |
| Zhang, C | 1 |
| Dou, QP | 1 |
| Liu, J | 1 |
| Shaiova, L | 1 |
| Fleishman, S | 1 |
| Klein, E | 1 |
| Lesage, P | 1 |
| Portenoy, R | 1 |
| Faivre, S | 1 |
| Chièze, S | 1 |
| Delbaldo, C | 1 |
| Ady-Vago, N | 1 |
| Guzman, C | 1 |
| Lopez-Lazaro, L | 1 |
| Lozahic, S | 1 |
| Jimeno, J | 1 |
| Pico, F | 1 |
| Armand, JP | 1 |
| Martin, JA | 1 |
| Raymond, E | 1 |
| Lusso, MR | 1 |
| Deiana, L | 2 |
| Lamonica, G | 1 |
| Spiga, C | 1 |
| Laviano, A | 1 |
| Meguid, MM | 1 |
| Guijarro, A | 1 |
| Muscaritoli, M | 1 |
| Cascino, A | 1 |
| Preziosa, I | 1 |
| Molfino, A | 1 |
| Rossi Fanelli, F | 1 |
| Mancinelli, A | 1 |
| D'Iddio, S | 1 |
| Bisonni, R | 2 |
| Graziano, F | 2 |
| Lippe, P | 1 |
| Calvani, M | 3 |
| Sood, A | 1 |
| Barton, DL | 1 |
| Bauer, BA | 1 |
| Loprinzi, CL | 1 |
| Hoang, BX | 1 |
| Graeme Shaw, D | 1 |
| Pham, P | 1 |
| Levine, S | 1 |
| Rogalidou, ME | 1 |
| Stiakaki, E | 1 |
| Evangeliou, A | 1 |
| Kalmanti, M | 1 |
| Mock, V | 1 |
| Atkinson, A | 1 |
| Barsevick, AM | 1 |
| Berger, AM | 1 |
| Cimprich, B | 1 |
| Eisenberger, MA | 1 |
| Hinds, P | 1 |
| Kaldor, P | 1 |
| Otis-Green, SA | 1 |
| Piper, BF | 1 |
| Sanna, E | 1 |
| Floris, C | 1 |
| Lissoni, P | 1 |
| Galli, MA | 1 |
| Tancini, G | 1 |
| Barni, S | 1 |
| Yazdanpanah, M | 1 |
| Luo, X | 1 |
| Lau, R | 1 |
| Greenberg, M | 1 |
| Fisher, LJ | 1 |
| Lehotay, DC | 1 |
| Heuberger, W | 1 |
| Berardi, S | 1 |
| Jacky, E | 1 |
| Pey, P | 1 |
| Krähenbühl, S | 1 |
| Kuratsune, H | 1 |
| Yamaguti, K | 1 |
| Lindh, G | 1 |
| Evengard, B | 1 |
| Takahashi, M | 1 |
| Machii, T | 1 |
| Matsumura, K | 1 |
| Takaishi, J | 1 |
| Kawata, S | 1 |
| Långström, B | 1 |
| Kanakura, Y | 1 |
| Kitani, T | 1 |
| Watanabe, Y | 1 |
| Breitkreutz, R | 1 |
| Babylon, A | 1 |
| Hack, V | 1 |
| Schuster, K | 1 |
| Tokus, M | 1 |
| Böhles, H | 1 |
| Hagmüller, E | 1 |
| Edler, L | 1 |
| Holm, E | 1 |
| Dröge, W | 1 |
| Nicolai, R | 2 |
| Reda, E | 2 |
| Benatti, P | 2 |
| Barbarisi, A | 2 |
| Catalano, V | 1 |
| Silva, R | 1 |
| Rovidati, S | 1 |
| Mencarini, E | 1 |
| Ferraro, B | 1 |
| Canestrari, F | 1 |
| Baldelli, AM | 1 |
| De Gaetano, A | 1 |
| Giordani, P | 1 |
| Testa, E | 1 |
| Lai, V | 1 |
| Chen, SH | 1 |
| Lincoln, SD | 1 |
| Dodson, WL | 2 |
| Sachan, DS | 2 |
| Krauss, S | 1 |
| Hanna, W | 1 |
| De Leonardis, V | 1 |
| Neri, B | 1 |
| Bacalli, S | 1 |
| Cinelli, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| A Single-arm, Open, Prospective, Multi-center Study on Thalidomide Combined With First-line Chemotherapy and Monotherapy for Maintenance Treatment of Liver Metastases From Her2-negative Advanced Gastric Cancer[NCT05198856] | Phase 1/Phase 2 | 106 participants (Anticipated) | Interventional | 2022-03-10 | Not yet recruiting | ||
| Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408] | Phase 3 | 184 participants (Actual) | Interventional | 2014-10-01 | Completed | ||
| Phase III Randomized Placebo-Controlled Trial to Determine Efficacy of Levocarnitine for Fatigue in Patients With Cancer[NCT00091169] | Phase 3 | 376 participants (Actual) | Interventional | 2005-12-16 | Completed | ||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Depression was measured using Center for Epidemiologic Studies Depression Scale (CES-D). The sum of the scores for all 20 items (range: 0-60) was used to assess depression level, and higher scores indicated a higher level of depression. Score change= CES-D score at 4 weeks - CES-D score at baseline. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Levocarnitine | -3.05 |
| Placebo | -2.91 |
Fatigue was measured using Brief Fatigue Inventory (BFI). The average of all 9 items included in the scale (range: 0-10) was used to measure fatigue level, and a higher average represented worse fatigue. Score change= BFI score at 4 weeks - BFI score at baseline. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Levocarnitine | -0.96 |
| Placebo | -1.11 |
Fatigue was measured using Functional Assessment of Cancer Therapy- Fatigue subscale (FACIT-F). The sum of the scores for all 13 items (range: 0-52) included in the scale was used to measure fatigue level, and lower score represented worse fatigue. Score change= FACIT-F score at 4 weeks - FACIT-F score at baseline. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Levocarnitine | 5.36 |
| Placebo | 4.04 |
Pain was measured using Brief Pain Inventory (BPI). The mean of the 4 severity items (range: 0-10 with 0 representing no pain and 10 representing pain as bad as you can imagine) was used to measure pain severity. Score change= BPI score at 4 weeks - BPI score at baseline. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Levocarnitine | -0.19 |
| Placebo | -0.08 |
Carnitine deficiency is defined as a ratio of acylcarnitine (total-free) to free carnitine > 0.4 μmol/L or free carnitine < 35 μmol/L for males and < 25 μmol/L for females. (NCT00091169)
Timeframe: assessed at 4 weeks after randomization
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I | 0.113 |
| Arm II | 0.333 |
Performance status (PS) was measured using Eastern Cooperative Oncology Group performance status scale. Lower score represents better PS. Change in PS was calculated by PS at week 4- PS at baseline. Patients with negative value for change in PS were considered to have stable or improving PS. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I | 0.806 |
| Arm II | 0.875 |
19 reviews available for carnitine and Benign Neoplasms
| Article | Year |
|---|---|
Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Carnitine; Doxorubicin; Humans; | 2022 |
Clinical Significance of Carnitine in the Treatment of Cancer: From Traffic to the Regulation.
Topics: Carcinogenesis; Carnitine; Cell Membrane; Clinical Relevance; Humans; Membrane Transport Proteins; N | 2023 |
SLC22A5 (OCTN2) Carnitine Transporter-Indispensable for Cell Metabolism, a Jekyll and Hyde of Human Cancer.
Topics: Biological Transport; Carnitine; Gene Expression Regulation, Neoplastic; Humans; Mitochondria; Neopl | 2019 |
Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis.
Topics: Carnitine; Dietary Supplements; Fatigue; Humans; Neoplasms | 2017 |
The carnitine system and cancer metabolic plasticity.
Topics: Biological Transport; Carnitine; Carnitine Acyltransferases; Carnitine O-Palmitoyltransferase; Energ | 2018 |
Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies.
Topics: Animals; Carnitine; Dietary Supplements; Disease Models, Animal; Humans; Muscle, Skeletal; Muscular | 2013 |
[Micronutrients in oncology. Current data about vitamin D, selenium, L-carnitine and vitamin C].
Topics: Antineoplastic Agents; Antioxidants; Ascorbic Acid; Carnitine; Humans; Micronutrients; Neoplasms; Nu | 2013 |
OCTN cation transporters in health and disease: role as drug targets and assay development.
Topics: Acetylcholine; Alzheimer Disease; Amino Acid Sequence; Animals; Biological Transport; Carnitine; Hum | 2013 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Advances in pharmacologic strategies for cancer cachexia.
Topics: Amino Acids; Body Weight; Cachexia; Carnitine; Clinical Trials as Topic; Cytokines; Dietary Suppleme | 2015 |
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Carnitine; Carnitine O-Palmitoyltransferase; Cytoplas | 2016 |
Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
Topics: Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiotoxicity; Carnitine; Child; Deficienc | 2016 |
A review of the logistic role of L-carnitine in the management of radiation toxicity and radiotherapy side effects.
Topics: Animals; Biomarkers; Carnitine; Disease Management; Disease Models, Animal; Homeostasis; Humans; Neo | 2011 |
Antimyopathic effects of carnitine and nicotine.
Topics: Animals; Anorexia; Cachexia; Carnitine; Energy Intake; Energy Metabolism; Humans; Kidney Failure, Ch | 2006 |
A critical review of complementary therapies for cancer-related fatigue.
Topics: Acupuncture Therapy; Adenosine Triphosphate; Carnitine; Complementary Therapies; Energy Metabolism; | 2007 |
Childhood malignant diseases: which is the carnitine's role?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carnitine; Humans; Neoplasms | 2007 |
Cancer-related fatigue. Clinical Practice Guidelines in Oncology.
Topics: Algorithms; Carnitine; Comorbidity; Counseling; Dietary Supplements; Disease Management; Fatigue; Hu | 2007 |
Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system.
Topics: Antineoplastic Agents; Carnitine; Energy Metabolism; Humans; Neoplasms | 2000 |
Carnitine system and tumor.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Carnitine; Diet; Humans; Neoplasms; Palmito | 1999 |
15 trials available for carnitine and Benign Neoplasms
| Article | Year |
|---|---|
Lower carnitine plasma values from malnutrition cancer patients.
Topics: Adolescent; Adult; Biomarkers; Cardiomyopathies; Carnitine; Case-Control Studies; Female; Follow-Up | 2013 |
L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study.
Topics: Aged; Anemia; Carnitine; Dietary Supplements; Double-Blind Method; Female; Humans; Karnofsky Perform | 2009 |
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.
Topics: Appetite Stimulants; Cachexia; Carnitine; Eicosapentaenoic Acid; Female; Humans; Interleukin-6; Male | 2010 |
Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Topics: Aged; Body Composition; Cachexia; Carnitine; Contraceptives, Oral, Hormonal; Eicosapentaenoic Acid; | 2010 |
Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Anorexia; Appetite; Cachexia; Carnitine; Celecoxib; | 2012 |
L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia.
Topics: Aged; Body Mass Index; Cachexia; Carnitine; Fat Emulsions, Intravenous; Female; Humans; Male; Middle | 2012 |
L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial.
Topics: Carnitine; Complementary Therapies; Dietary Supplements; Double-Blind Method; Fatigue; Female; Human | 2012 |
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carnitine; Depsipeptides; Dose-Response Relationship | 2005 |
Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area U | 2007 |
Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study.
Topics: Administration, Oral; Carnitine; Dietary Supplements; Dose-Response Relationship, Drug; Drug Adminis | 2006 |
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antioxidants; | 2008 |
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy.
Topics: Adult; Aged; Cardiomyopathies; Carnitine; Drug Therapy, Combination; Female; Heart Diseases; Humans; | 1993 |
Increased urinary excretion of carnitine in patients treated with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents; Blood Glucose; Carnitine; Cisplatin; Drug Interactions; Female; | 1998 |
Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases.
Topics: Adult; Aged; Animals; Cachexia; Carnitine; Double-Blind Method; Extremities; Female; Glutamic Acid; | 2000 |
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam | 2002 |
32 other studies available for carnitine and Benign Neoplasms
| Article | Year |
|---|---|
Determinants of blood acylcarnitine concentrations in healthy individuals of the European Prospective Investigation into Cancer and Nutrition.
Topics: Carnitine; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Neoplasms; Prospective Studies | 2022 |
The Association of Serum L-Carnitine Concentrations with the Risk of Cancer in Chinese Adults with Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; East Asian People; Female; Humans; Hypertension; Male; Methy | 2022 |
The Association of Serum L-Carnitine Concentrations with the Risk of Cancer in Chinese Adults with Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; East Asian People; Female; Humans; Hypertension; Male; Methy | 2022 |
The Association of Serum L-Carnitine Concentrations with the Risk of Cancer in Chinese Adults with Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; East Asian People; Female; Humans; Hypertension; Male; Methy | 2022 |
The Association of Serum L-Carnitine Concentrations with the Risk of Cancer in Chinese Adults with Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; East Asian People; Female; Humans; Hypertension; Male; Methy | 2022 |
Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia.
Topics: 3-Hydroxybutyric Acid; Adipocytes; Biotin; Cachexia; Carnitine; Catechin; Coumaric Acids; Dietary Su | 2019 |
Mass Spectrometry Fingerprints of Small-Molecule Metabolites in Biofluids: Building a Spectral Library of Recurrent Spectra for Urine Analysis.
Topics: Body Fluids; Carnitine; Chromatography, Liquid; Humans; Mass Spectrometry; Neoplasms; Small Molecule | 2019 |
Polymorphisms in
Topics: Carnitine; Carnitine O-Palmitoyltransferase; Genotype; Humans; Neoplasms; Polymorphism, Genetic | 2019 |
Quantitation of Urinary Acylcarnitines by DMS-MS/MS Uncovers the Effects of Total Body Irradiation in Cancer Patients.
Topics: Animals; Biomarkers; Carnitine; Humans; Neoplasms; Pilot Projects; Rats, Sprague-Dawley; Tandem Mass | 2020 |
A redox-activatable biopolymer-based micelle for sequentially enhanced mitochondria-targeted photodynamic therapy and hypoxia-dependent chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biopolymers; Carnitine; Cell Line, Tumor; Humans; Hyaluro | 2020 |
Dynamics of L-Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy.
Topics: Antineoplastic Agents; Body Mass Index; Carnitine; Cisplatin; Female; Glomerular Filtration Rate; Hu | 2017 |
Plasma L-carnitine levels in terminally ill cancer patients receiving only palliative care.
Topics: Carnitine; Case-Control Studies; Female; Hospitalization; Humans; Japan; Male; Middle Aged; Neoplasm | 2017 |
Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines.
Topics: Adolescent; Adult; Anthracyclines; Cardiomyopathies; Cardiovascular Diseases; Carnitine; Child; Fema | 2014 |
Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Child, Preschool; Cisplatin; Dose-Response Rela | 2015 |
[Experience with levocarnitine chloride supplementation for the treatment of fatigue in cancer patients undergoing chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carnitine; Fatigue; Female; Humans; Male; Mid | 2014 |
Two novel compounds of vanadium and molybdenum with carnitine exhibiting potential pharmacological use.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carnitine; Coordination Complexes; Drug Screening Assays | 2015 |
A cross-sectional study of carnitine deficiency and fatigue in pediatric cancer patients.
Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Chromatography, Liquid; Cross-Sectional Studies | 2016 |
Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study.
Topics: Biomarkers, Tumor; Breast Neoplasms; Carnitine; Cohort Studies; Colorectal Neoplasms; Female; Humans | 2016 |
Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; beta 2-Microglobulin; Carnitine; Cisplatin; Fatigue; Female; Hum | 2017 |
Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.
Topics: Adenosine Triphosphate; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2009 |
L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase.
Topics: Animals; Blood Glucose; Cachexia; Carnitine; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Cho | 2011 |
L-carnitine and cancer cachexia. II. Effects of lipid emulsion used in total parenteral nutrition on parameters of hemostasis and inflammatory state in L-carnitine deficiency in myocytes.
Topics: Aged; Body Mass Index; Cachexia; Carnitine; Fat Emulsions, Intravenous; Female; Hemostasis; Humans; | 2012 |
L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer.
Topics: Animals; Cachexia; Carcinoma, Hepatocellular; Carnitine; Caspase 3; Dietary Supplements; Liver Neopl | 2012 |
Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carnitine; Cell Line, Tumor; Drug Resistance, Neopla | 2012 |
L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro.
Topics: Acetylation; Adenosine Triphosphate; Animals; Carnitine; Cell Line, Tumor; Cell Proliferation; Chrom | 2012 |
L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis.
Topics: Carnitine; Depression; Dietary Supplements; Fatigue; Female; Humans; Male; Middle Aged; Neoplasms; R | 2004 |
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carnitine; Cytokines; Dietary Supplements; Fatigue; Female; Glut | 2006 |
Understanding and treating cancer-related fatigue.
Topics: Carnitine; Confounding Factors, Epidemiologic; Cytokines; Fatigue; Humans; Neoplasms; Vitamin B Comp | 2006 |
Restoration of cellular energetic balance with L-carnitine in the neuro-bioenergetic approach for cancer prevention and treatment.
Topics: Carnitine; Cell Membrane; Energy Metabolism; Mitochondria; Neoplasms; Neurotransmitter Agents; Vitam | 2007 |
Cytotoxic aldehydes as possible markers for childhood cancer.
Topics: Adolescent; Aldehydes; Biomarkers, Tumor; Bone Neoplasms; Burkitt Lymphoma; Carnitine; Child; Child, | 1997 |
Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases.
Topics: Acute Disease; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Fatigu | 1998 |
Increased serum carnitine concentration in renal insufficiency.
Topics: Adult; Blood Urea Nitrogen; Carnitine; Coronary Disease; Humans; Kidney Diseases; Liver Cirrhosis; M | 1977 |
Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance.
Topics: Carnitine; Female; Humans; Male; Middle Aged; Neoplasms | 1989 |
The serum carnitine status of cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carnitine; Esters; Female; Humans; Male; Middle Aged; Neoplasms | 1987 |
Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Carnitine; Creatine Kinase; Doxorubicin; Echoc | 1985 |